TrialEuropean journal of clinical pharmacology2017

First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases.

Eric Helmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.